Use of Mobile and Sensor Technology Lowers Symptom Severity for People With Head and Neck Cancer

For immediate release
May 16, 2018

MEDIA CONTACT:
Kelly Baldwin
571-483-1365
kelly.baldwin@asco.org

PATIENT AND CAREGIVER INQUIRIES:
Contact Cancer.Net
ASCO Perspective

“This study demonstrates the power of leveraging smart technology to improve the care of people with cancer. These tools helped simplify care for both patients and their care providers by enabling emerging side effects to be identified and addressed quickly and efficiently to ease the burden of treatment. I hope that these or similar technologies will be broadly available to patients soon,” said ASCO President Bruce E. Johnson, MD, FASCO.

ALEXANDRIA, Va. – A federally funded, randomized clinical trial of 357 people receiving radiation for head and neck cancer, using mobile and sensor technology to remotely monitor patient symptoms, resulted in less severe symptoms related to both the cancer and its treatment (both general and cancer-related).

Patients who used the technology – which included a Bluetooth-enabled weight scale, Bluetooth-enabled blood pressure cuff, and mobile tablet with a symptom-tracking app that sent information directly to their physician each weekday – had lower symptom severity than participants who had standard weekly visits with their doctors.

In addition, daily remote tracking of patient wellbeing, according to the researchers, enabled physicians to detect concerning symptoms early and respond more rapidly, compared to usual care. These findings will be presented at the upcoming 2018 ASCO Annual Meeting in Chicago.

“Our study generated evidence on how newer technologies can be integrated into cancer care relatively easily and improve patient outcomes without interfering too much in a person’s daily life,” said lead study author Susan K. Peterson, PhD, professor, Department of Behavioral Science, The University of Texas MD Anderson Cancer Center, Houston. “This study was done during a rather intense period in the patients’ care for head and neck cancer. The system helped their physicians to provide valuable support that ultimately resulted in lower symptom severity.”

About Head and Neck Cancer

An estimated 51,540 new head and neck cancers will be diagnosed in the United States in 2018. Just over 10,000 people are expected to die of the disease, with men accounting for
three-quarters of these deaths.

Most people diagnosed with this form of cancer receive radiation therapy but can also have chemotherapy or surgery. One of the major side effects of treatment that requires careful monitoring is pain and difficulty swallowing, which can lead to dehydration.

**About the Study**

This trial used a technology system called CYCORE (CYberinfrastructure for COmparative Effectiveness REsearch), developed collaboratively by four institutions through a grant from the National Cancer Institute.

Participants were randomly assigned to CYCORE (169 people) or usual care (188 people), which consisted of weekly doctor visits. People in the CYCORE group received sensors (blood pressure cuffs and weight scales) that were Bluetooth-enabled. They also got mobile tablets with proprietary Wi-Fi. An in-home wide area network (WAN) hub/router transmitted their sensor readouts, and a mobile app transmitted their symptom data through a back-end cyber-infrastructure to secure firewall-protected computers at MD Anderson to ensure patient information confidentiality.

For the CYCORE group, physicians reviewed data from the app and sensor transmissions remotely each weekday and could intervene in a person’s care if necessary. Both CYCORE and usual care participants had weekly in-person doctor visits.

At the start of radiation therapy, study participants completed a 28-item MD Anderson Symptom Inventory survey about their health and common activities of daily living. The survey covered general symptoms that are common in people with cancer, such as pain, fatigue, and nausea, as well as symptoms that are particularly relevant to people with head and neck cancer, such as difficulty swallowing or chewing, skin pain/burning/rash, and problems with tasting food. The participants completed a similar survey at the end of their radiation therapy, usually 6 to 7 weeks later. A final survey was completed 6 to 8 weeks after their radiation therapy ended.

**Key Findings**

There was no difference in self-reported health severity scores between the CYCORE participants and those who received usual care at the start of the trial. Symptoms severity
was scored on a scale of 0 to 10, with zero being no symptom or pain and 10 being the highest level of symptom severity. After completion of radiation therapy, the CYCORE participants had lower (i.e. better) mean scores for general symptoms vs. usual care participants (2.9 vs. 3.4), as well as lower mean scores for symptoms specific to head and neck cancer (4.2 vs. 4.8).

Six to 8 weeks after completion of therapy, CYCORE participants had a mean score of 1.6 vs. 1.9 for usual care participants based on overall health. Both groups had slightly higher severity scores for specific head and neck symptoms (1.7 vs. 2.1).

Most patients (80% or more) adhered to daily monitoring, which was an excellent outcome given the intensity of their treatments, noted Dr. Peterson. Scores reflecting how various symptoms interfered in activities of daily living were about the same in both groups across the entire time of survey reporting.

Limitations and Next Steps
While the authors were able to recruit people from a wide range of ages, the study population was mostly white, which closely reflected the overall head and neck patient population at the cancer center. The next step for researchers may be to determine how long the benefit of a CYCORE intervention could persist. They also hope to implement the CYCORE intervention in non-academic cancer treatment settings where the majority of cancer patients receive their treatment.

This study received funding from the National Institutes of Health.

Study at a Glance

<table>
<thead>
<tr>
<th>Disease</th>
<th>Head and Neck Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trial Type</td>
<td>Randomized</td>
</tr>
<tr>
<td>Patients on Trial</td>
<td>357</td>
</tr>
<tr>
<td>Intervention Tested</td>
<td>Tracking and transmitting symptoms through sensor and mobile devices vs. usual care</td>
</tr>
<tr>
<td>Primary Finding</td>
<td>Severity of symptoms at baseline, post-therapy, and 6-8 weeks post-therapy</td>
</tr>
</tbody>
</table>
For your readers:

- Guide to Head and Neck Cancer
- Understanding Radiation Therapy
- Dehydration

View the disclosures for the 2018 ASCO Annual Meeting News Planning Team.

Disclosures for Bruce E. Johnson, MD, FASCO: Stock and Other Ownership Interests with KEW Group; Honoria from Merck and Chugai Pharma; Consulting or Advisory Role with Novartis, AstraZeneca (Inst.), KEW Group, Merck, Transgene, Clovis Oncology, Genentech, Lilly (Inst.), Chugai Pharma, Boehringer Ingelheim and Amgen; Research Funding with Novartis; Patents, Royalties and Other Intellectual Property with royalties from Dana-Farber Cancer Institute; Expert Testimony with Genentech.

ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL COVERAGE.

###


About ASCO:

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents nearly 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at [www.ASCO.org](http://www.ASCO.org), explore patient education resources at [www.Cancer.Net](http://www.Cancer.Net), and follow us on Facebook, Twitter, LinkedIn, and YouTube.